4//SEC Filing
ZANTE GREG 4
Accession 0000950170-24-117885
CIK 0001607678other
Filed
Oct 27, 8:00 PM ET
Accepted
Oct 28, 9:48 PM ET
Size
33.5 KB
Accession
0000950170-24-117885
Insider Transaction Report
Form 4
ZANTE GREG
Chief Financial Officer
Transactions
- Sale
Common Stock, par value $0.00001 per share
2024-10-28$80.65/sh−7,967$642,545→ 150,572 total - Sale
Common Stock, par value $0.00001 per share
2024-10-28$81.44/sh−1,206$98,222→ 149,366 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-28−12,750→ 0 totalExercise: $7.77From: 2021-01-03Exp: 2030-01-03→ Common Stock (12,750 underlying) - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-10-28$7.77/sh+12,750$99,068→ 199,802 total - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-10-28$8.52/sh+51,000$434,520→ 281,053 total - Sale
Common Stock, par value $0.00001 per share
2024-10-28$76.94/sh−9,265$712,803→ 203,496 total - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-10-28$4.68/sh+4,251$19,895→ 204,053 total - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-10-28$5.80/sh+26,000$150,800→ 230,053 total - Sale
Common Stock, par value $0.00001 per share
2024-10-28$79.78/sh−6,050$482,665→ 158,539 total - Sale
Common Stock, par value $0.00001 per share
2024-10-28$74.56/sh−49,672$3,703,495→ 231,381 total - Sale
Common Stock, par value $0.00001 per share
2024-10-28$77.68/sh−23,082$1,793,019→ 180,414 total - Sale
Common Stock, par value $0.00001 per share
2024-10-28$78.69/sh−15,825$1,245,280→ 164,589 total - Sale
Common Stock, par value $0.00001 per share
2024-10-28$75.79/sh−18,620$1,411,135→ 212,761 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-28−4,251→ 0 totalExercise: $4.68From: 2021-03-31Exp: 2030-03-31→ Common Stock (4,251 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-28−26,000→ 0 totalExercise: $5.80From: 2022-01-04Exp: 2031-01-04→ Common Stock (26,000 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-10-28−51,000→ 153,000 totalExercise: $8.52From: 2024-01-03Exp: 2033-01-03→ Common Stock (51,000 underlying)
Footnotes (12)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on July 29, 2024 by the Reporting Person.
- [F10]25% of the shares subject to the option vested on each anniversary of the grant date.
- [F11]One-third of the shares subject to the option vested on each anniversary of the grant date.
- [F12]25% of the shares subject to the option vested or will vest on each anniversary of the grant date.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.24 to $75.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.24 to $76.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $76.27 to $77.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $77.27 to $78.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.27 to $79.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F7]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.29 to $80.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F8]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.30 to $81.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.35 to $81.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
Documents
Issuer
Viking Therapeutics, Inc.
CIK 0001607678
Entity typeother
Related Parties
1- filerCIK 0001264949
Filing Metadata
- Form type
- 4
- Filed
- Oct 27, 8:00 PM ET
- Accepted
- Oct 28, 9:48 PM ET
- Size
- 33.5 KB